Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )
19 Dec 2019

Implementation of genetic testing in breast cancer patients

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA
Implementation of genetic testing in breast cancer patients ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )
19 Dec 2019

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA
Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )
19 Dec 2019

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women

Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
19 Dec 2019

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )
19 Dec 2019

Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
19 Dec 2019

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni -  San Raffaele Hospital, Milan, Italy )
18 Dec 2019

Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
18 Dec 2019

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
18 Dec 2019

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )
18 Dec 2019

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
18 Dec 2019